This is a Promoted Post!
RA Pathogenesis, Patient Goals and Traditional Treatment Course for Moderate-To-Severe Disease
- : Sydney NSW 2000
As the management of rheumatoid arthritis (RA) is centred around improving quality of life, it is crucial for to take into consideration patients' goals regarding desired treatment outcomes. This module explores the risk factors for developing RA, patient expectations for treatment and the efficacy of newly developed pharmacological agents.
Upon completion of this module the participant should be able to:
- Describe the role of cytokines, particularly IL-6, in the pathogenesis and treatment of RA
- Assess new data and recent treatment recommendation updates regarding the use of DMARDs for moderate to severe RA
- Select appropriate, individualised initial and escalation therapies for patients with RA
- Integrate patient-reported outcomes scales to assess and document treatment effectiveness in clinical practice
Disclosure of Conflicts of Interest
Roy Fleischmann, MD, MACR
Consultant/Advisor: Amgen Inc, AbbVie Inc, Bristol-Myers Squibb Company, Janssen Pharmaceutical Companies, Pfizer Inc, Sanofi-Regeneron, UCB Inc.
Grant/Research Support: Amgen Inc, AbbVie Inc, Bristol-Myers Squibb Company, Janssen Pharmaceutical Companies, Pfizer Inc, Sanofi-Regeneron, UCB Inc.
Speakers' Bureau: Pfizer Inc.
Stephen Hall, MBBS, MMSc, FRACP
No relationships to disclose
Christina M. Ohnsman, MD; Jessica Marshall, PhD; Lou Settembrino; Sandy Breslow; Alison Kemp; and Bernarnd M. Abrams hereby state that neither they nor their spouse/life partner have had any financial relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
This activity has been supported by an independent educational grant from Genzyme, a Sanofi Company and Regeneron Pharmaceuticals.
Jointly provided by the Elsevier Office of Continuing Medical Education, ASiM, In Vivo Academy Limited, and Reed Medical Education.